benaglutide + metformin

A combination therapy comprising benaglutide (also known as beinaglutide) and metformin, utilized for the management of metabolic and endocrine disorders. Benaglutide is a recombinant human glucagon-like peptide-1 (GLP-1) receptor agonist with 100% sequence homology to endogenous human GLP-1(7-36), developed by Shanghai Benemae Pharmaceutical Corporation. Metformin is a biguanide antihyperglycemic agent that improves insulin sensitivity and reduces hepatic glucose production. This combination is primarily investigated for type 2 diabetes mellitus, obesity, and polycystic ovary syndrome (PCOS), where it has demonstrated superior efficacy in weight reduction, BMI improvement, and glycemic control compared to metformin monotherapy. Benaglutide is typically administered via subcutaneous injection three times daily before meals, while metformin is taken orally.

Other names

beinaglutide + metforminrhGLP-1 + metformin